NeuroLucent is an early-stage company focused on developing small-molecule therapeutics to treat the cognitive loss associated with Alzheimer's disease. We are targeting Ca2+ dysregulation, an established hallmark of AD neurons. The NeuroLucent team has uncovered a key intracellular Ca2+ channel that is over-expressed and hyperactive in AD neurons. Preclinical validation has been achieved through the identification of compounds that normalize Ca2+ levels and decrease disease markers in animal models. NeuroLucent is currently focused on identifying a clinical candidate.
| Website | http://www.neurolucent.com |
| Revenue | $5 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2016 |
| Address | 3333 Green Bay Rd, North Chicago, Illinois 60064, US |
| Industry | Mental Health Care, Biotechnology, Drug Discovery, Pharmaceuticals, Healthcare |
| Keywords | Alzheimers Therapeutics, Alzheimers Research, Cognitive Impairment Treatment, Small Molecule Drugs, Cognitive Decline, Memory Loss Treatment, Neurodegenerative Disease Treatment, Neuroscience, Drug Discovery, Therapeutic Development, Neurological Disorders, Molecular Medicine, Brain Health, Pharmaceutical Research, Clinical Trials, Biotechnology, Preclinical Development |
| Competitors | NeuroPace, EMOTIV, Neurable, Neuroelectrics, NeuroSky, Hapbee, OpenBCI, BRAINCO INC., Muse.com Inc, MindWave +26 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies |
Looking for a particular NeuroLucent employee's phone or email?
NeuroLucent Questions
The NeuroLucent annual revenue was $5 million in 2026.
NeuroLucent is based in North Chicago, Illinois.
The NAICS codes for NeuroLucent are [541, 5417, 54].
The SIC codes for NeuroLucent are [87, 873].
Related Companies
